Navigation Links
Trillium and Biogen Idec enter into global license agreement
Date:1/12/2010

TORONTO, Jan. 12 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered into a definitive license agreement with Biogen Idec ( BIIB), granting the latter exclusive worldwide rights to one of Trillium's development programs.

"Biogen Idec is a premier biotechnology partner and a world leader in immunology research and development", commented Trillium CEO, Dr. Niclas Stiernholm. "We have had the privilege and fortune to work with some of the world's best immunology companies over the past few years, which reinforces the value and quality of our strong and innovative science."

"The Biogen Idec partnership clearly adds value and strongly validates the quality of our programs" underlined Luc Marengère, lead investor and Managing General Partner with VG Partners.

Under the terms of the agreement, TTI will receive an upfront payment and is eligible to receive milestone payments based on achievements of specified clinical, regulatory and commercial accomplishments. TTI will also receive royalties on global product sales. No other financial terms were disclosed. Biogen Idec will be solely responsible for clinical development, regulatory approvals, manufacturing and commercialization.

"Trillium's strong immunology foundation and its close connection to Toronto's world class immunology research community, has allowed it to build a suite of exciting biologies opportunities in the immunoregulatory field", added Dr. Michael Moore, Trillium's Chairman. "We look forward to concluding additional partnerships later in the year, particularly around our non-core assets."

About Trillium:

Trillium Therapeutics Inc. is a private biopharmaceutical company specializing in innovative therapies of immune-mediated conditions, such as autoimmune and inflammatory disorders, as well as cancer. The company's lead program, TTI-1612, is a recombinant growth factor that is being developed for the treatment of interstitial cystitis (IC) and the prevention of necrotizing enterocolitis (NEC). Trillium has broad portfolio preclinical immunology programs, including two that target the CD200 immunoregulatory axis; a CD200-specific monoclonal antibody for the treatment of cancer, and a CD200Fc fusion protein for the treatment of autoimmune and inflammatory diseases. In addition, the company has an FcyRlla-specific humanized monoclonal antibody in development for treatment of immune complex-mediated inflammatory diseases.

The company has a broad network of external academic and industry R&D collaborations, including several license agreements with major US biotechnology companies. The Company is supported by three premier venture capital investors: Vengrowth Private Equity Partners, Growthworks Capital and BDC Capital.

SOURCE Trillium Therapeutics Inc.


'/>"/>
SOURCE Trillium Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
2. Trillium Strengthens its Board of Directors
3. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
4. Biogenerics Will Save Billions, Says Hospira CEO
5. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
6. Icahn Confirms Intention to Nominate Three Directors at Biogen
7. Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation
8. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
9. CBO: Biogenerics Would Save Federal Government $6.6 Billion Over Ten Years
10. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
11. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... (PRWEB) , ... June 19, 2017 , ... ... solutions for clinical development reported today that it is launching two new additions ... company will be demonstrating new capabilities at the DIA 2017 Annual Meeting in ...
(Date:6/16/2017)... ... , ... CTNext , Connecticut’s go-to resource for entrepreneurial support, today announced ... Chelsea Piers in Stamford. , Nine finalists, all of whom are Connecticut-based companies and ... to secure $10,000 awards to help support business growth. The winners included:, ...
(Date:6/15/2017)... ... 2017 , ... DuPont Industrial Biosciences (DuPont) announced that Jan ... Bloomberg’s 2017 Sustainable Business Summit: Seattle this Thursday, June 15, at 4:10 ... panel titled “Developing a Corporate Renewables Strategy.” , “Consumers want to buy ...
(Date:6/14/2017)... ... ... Diagenode, a leading global provider for complete solutions for ... technology specific for ChIP-sequencing from the CeMM for low ... (ChIP-seq) allows the study of histone modifications and transcription ...
Breaking Biology Technology:
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
(Date:3/22/2017)... YORK , March 21, 2017 ... Marketing Cloud used by retailers such as 1-800-Flowers ... its platform — Product Recommendations and Replenishment. Using Optimove,s ... give more personalized product and replenishment recommendations to ... but also on predictions of customer intent drawn ...
Breaking Biology News(10 mins):